Patient characteristics before first postibrutinib treatment
| Characteristics postibrutinib . | Number . | % . |
|---|---|---|
| All | 104 | 100% |
| Received treatment postibrutinib | 73 | 70% |
| Time from ibrutinib to next therapy | 0.3 mo | 95% CI, 0.2-0.5 |
| MIPI scores at start of therapy | ||
| High risk | 35 | 48% |
| Intermediate risk | 18 | 25% |
| Low risk | 9 | 12% |
| Unknown | 11 | 15% |
| Ki67 >30% | 11/12 | 92% |
| Subsequent treatment | ||
| Rituximab | 39 | 53% |
| Lenalidomide | 19 | 26% |
| Cytarabine | 13 | 18% |
| Bendamustine | 12 | 16% |
| Bortezomib | 7 | 10% |
| Anthracycline | 5 | 7% |
| PI3K inhibitor | 4 | 5% |
| Characteristics postibrutinib . | Number . | % . |
|---|---|---|
| All | 104 | 100% |
| Received treatment postibrutinib | 73 | 70% |
| Time from ibrutinib to next therapy | 0.3 mo | 95% CI, 0.2-0.5 |
| MIPI scores at start of therapy | ||
| High risk | 35 | 48% |
| Intermediate risk | 18 | 25% |
| Low risk | 9 | 12% |
| Unknown | 11 | 15% |
| Ki67 >30% | 11/12 | 92% |
| Subsequent treatment | ||
| Rituximab | 39 | 53% |
| Lenalidomide | 19 | 26% |
| Cytarabine | 13 | 18% |
| Bendamustine | 12 | 16% |
| Bortezomib | 7 | 10% |
| Anthracycline | 5 | 7% |
| PI3K inhibitor | 4 | 5% |
MIPI, Mantle Cell Lymphoma International Prognostic Index.